Unlock instant, AI-driven research and patent intelligence for your innovation.

Survivin specific T-cell receptor targeting tumor but not T cells

A cell receptor and survivin technology, applied in the direction of tumor/cancer cells, receptors/cell surface antigens/cell surface determinants, cells modified by introducing foreign genetic material, etc., can solve severe toxicity and other problems

Inactive Publication Date: 2017-08-01
BAYLOR COLLEGE OF MEDICINE
View PDF17 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these approaches have been severely toxic due to unrecognized cross-reactivity of targeted epitopes from the repertoire of unrelated proteins that can be expressed by healthy tissues (Cameron et al., 2013; Linette et al., 2013)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Survivin specific T-cell receptor targeting tumor but not T cells
  • Survivin specific T-cell receptor targeting tumor but not T cells
  • Survivin specific T-cell receptor targeting tumor but not T cells

Examples

Experimental program
Comparison scheme
Effect test

example

[0180] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of ordinary skill in the art should, in light of the present invention, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or a similar result without departing from the spirit and scope of the invention.

example 1

[0182] Generation of autologous survivin-specific T cell clones with selective antitumor effects

[0183] Use from HLA-A*02 + Peripheral blood samples collected from healthy donors, using survivin 95-104 Survivin 96-104 97M (termed LML; LMLGEFLKL; SEQ ID NO: 16), produces survivin restricted to HLA-A*0201 95-104 (referred to as ELT; ELTLGEFLKL; SEQ ID NO: 15) epitope specific CD8 + Cytotoxic T cells (CTLs) (Andersen et al., 2001).

[0184] After 3 antigen-specific stimulations, 3 of 5 CTL strains (from donors #2, 4, and 5) compared with LML (643±5, 49±1 and 96±7 SFC / 10 5 T cells) and ELT peptides (662±65, 45±6 and 86±9SFC / 10 5 T cells) specific response. By limiting dilution from the most responsive donor (#2) and generating individual T cell clones using multiple assays comparing survivin-specific and non-specific (irrelevant) clones, the optimal functional parent was identified. A joint force. Specifically, clone #24 showed the highest specificity (>99%) for LML-te...

example 2

[0190] Polyclonal T cells engineered to express survivin-specific TCRs are not self-mutilating

[0191] After replacement of the constant regions with the corresponding murine regions, the TCR α and β chains of clone #24 (designated s24-TCR hereafter) were cloned, codon-optimized and encoded into a retroviral vector ( figure 2 A). The TCR chain utilization and complementarity-determining regions are completely different from previously published self-mutilating TCRs (Tables 2 and 3).

[0192] Table 2. Survivin-specific TCR alpha chain utilization.

[0193]

[0194] Nomenclature according to the International Immunogenetics Information System website www.jmgt.org . The sequences of TCRs A66, A71 and A72 are published allotopically restricted survivin-specific TCRs with self-mutilating effects (Leisegang, 2010).

[0195] Table 3. Survivin-specific TCR beta chain utilization.

[0196]

[0197] Nomenclature according to the International Immunogenetics Information Sys...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Embodiments of the disclosure concern engineered T cell receptors that are specific for the survivin tumor antigen but do not have "on-target off tumor" toxicity. In particular embodiments, particular alpha and beta chains are utilized in engineered T cell receptors for cell therapy that have effective anti-tumor activity but lack fratricidal effects. Methods, compositions, and kits are provided herein.

Description

[0001] This application claims priority to US Provisional Patent Application Serial No. 62 / 073,076, filed October 31, 2014, which is hereby incorporated by reference in its entirety. [0002] Statement Regarding Federally Sponsored Research or Development [0003] This invention was made with government support under R01CA131027 and P50CA126752 awarded by the National Cancer Institute. The government has certain rights in this invention. technical field [0004] Embodiments of the invention relate to at least the fields of immunology, cell biology, molecular biology, and medicine, including cancer medicine. Background technique [0005] Adoptive T-cell therapy targeting cancer using genetically engineered αβ T-cell receptors (TCRs) has produced encouraging responses in some patients (Morgan et al., 2006; Johnson et al. , 2009; Robbins et al., 2011). Broadening this approach to a larger array of malignancies requires targeting more broadly expressed tumor-associated antig...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/10C07K14/705C07K14/725
CPCC07K14/7051C12N5/0636C12N2510/00C12N5/0694A61P35/00A61P35/02A61K39/4632A61K2239/31A61K39/4611A61K2239/38A61K2239/26A61K39/46445A61K2239/48C07K14/705
Inventor B·索沃尔多G·多蒂C·E·阿尔伯巴斯
Owner BAYLOR COLLEGE OF MEDICINE